CN115066425A - Jak抑制剂在制备治疗jak激酶相关疾病药物中的应用 - Google Patents

Jak抑制剂在制备治疗jak激酶相关疾病药物中的应用 Download PDF

Info

Publication number
CN115066425A
CN115066425A CN202080094355.5A CN202080094355A CN115066425A CN 115066425 A CN115066425 A CN 115066425A CN 202080094355 A CN202080094355 A CN 202080094355A CN 115066425 A CN115066425 A CN 115066425A
Authority
CN
China
Prior art keywords
compound
formula
use according
compounds
isomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080094355.5A
Other languages
English (en)
Other versions
CN115066425B (zh
Inventor
王帅
王德刚
吴守廷
于婷婷
房淼
穆利伟
方亮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhuhai United Laboratories Co Ltd
Original Assignee
Zhuhai United Laboratories Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhuhai United Laboratories Co Ltd filed Critical Zhuhai United Laboratories Co Ltd
Publication of CN115066425A publication Critical patent/CN115066425A/zh
Application granted granted Critical
Publication of CN115066425B publication Critical patent/CN115066425B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Abstract

一种JAK抑制剂[1,2,4]三唑并[1,5‑a]吡啶类化合物在制备治疗自身免疫性、炎症性或变应性疾病，或者移植排斥等疾病的应用，所述JAK抑制剂[1,2,4]三唑并[1,5‑a]吡啶类化合物包括式(Ⅰ)所示化合物、其异构体或其药学上可接受的盐。所述JAK抑制剂在自身免疫性、炎症性或变应性等疾病的动物模型试验中具有良好药效。
Figure DDA0003752188280000011

Description

PCT国内申请，说明书已公开。

Claims (23)

  1. PCT国内申请，权利要求书已公开。
CN202080094355.5A 2020-02-13 2020-02-13 Jak抑制剂在制备治疗jak激酶相关疾病药物中的应用 Active CN115066425B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2020/075024 WO2021159372A1 (zh) 2020-02-13 2020-02-13 Jak抑制剂在制备治疗jak激酶相关疾病药物中的应用

Publications (2)

Publication Number Publication Date
CN115066425A true CN115066425A (zh) 2022-09-16
CN115066425B CN115066425B (zh) 2023-06-23

Family

ID=77292614

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080094355.5A Active CN115066425B (zh) 2020-02-13 2020-02-13 Jak抑制剂在制备治疗jak激酶相关疾病药物中的应用

Country Status (8)

Country Link
US (1) US20230113620A1 (zh)
EP (1) EP4105214A4 (zh)
JP (1) JP7395762B2 (zh)
KR (1) KR20220127900A (zh)
CN (1) CN115066425B (zh)
AU (1) AU2020428591A1 (zh)
CA (1) CA3169832A1 (zh)
WO (1) WO2021159372A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230091250A1 (en) * 2020-02-21 2023-03-23 Zhuhai United Laboratories Co., Ltd. Crystalline form of jak inhibitor and application thereof
US20240033255A1 (en) * 2021-01-29 2024-02-01 Zhuhai United Laboratories Co., Ltd. Oral preparation containing jak inhibitor or salt thereof or crystal form thereof, preparation method therefor, and application thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010010187A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2011006074A1 (en) * 2009-07-09 2011-01-13 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS
CN104262337A (zh) * 2009-06-26 2015-01-07 加拉帕戈斯股份有限公司 作为jak抑制剂的5-苯基-[1,2,4]三唑并[1,5-a]吡啶-2-甲酰胺化合物
WO2018032104A1 (en) * 2016-08-17 2018-02-22 Pharmascience Inc. Spirocyclic containing compounds and pharmaceutical uses thereof
CN107759587A (zh) * 2016-08-19 2018-03-06 中国医药研究开发中心有限公司 [1,2,4]三唑并[1,5‑a]吡啶类化合物及其制备方法和医药用途
CN108341814A (zh) * 2017-01-23 2018-07-31 上海翔锦生物科技有限公司 Jak激酶抑制剂及其应用
CN112739696A (zh) * 2018-08-23 2021-04-30 珠海联邦制药股份有限公司 作为JAK抑制剂的[1,2,4]三唑并[1,5-a]吡啶类化合物及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090220688A1 (en) 2005-07-27 2009-09-03 Buddy Tools, Llc Drywall tape and joint compound dispenser
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
WO2018019222A1 (zh) 2016-07-26 2018-02-01 张文燕 作为jak抑制剂杂环化合物，该化合物的盐类及其治疗用途

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010010187A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
CN104262337A (zh) * 2009-06-26 2015-01-07 加拉帕戈斯股份有限公司 作为jak抑制剂的5-苯基-[1,2,4]三唑并[1,5-a]吡啶-2-甲酰胺化合物
WO2011006074A1 (en) * 2009-07-09 2011-01-13 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS
WO2018032104A1 (en) * 2016-08-17 2018-02-22 Pharmascience Inc. Spirocyclic containing compounds and pharmaceutical uses thereof
CN107759587A (zh) * 2016-08-19 2018-03-06 中国医药研究开发中心有限公司 [1,2,4]三唑并[1,5‑a]吡啶类化合物及其制备方法和医药用途
CN108341814A (zh) * 2017-01-23 2018-07-31 上海翔锦生物科技有限公司 Jak激酶抑制剂及其应用
CN112739696A (zh) * 2018-08-23 2021-04-30 珠海联邦制药股份有限公司 作为JAK抑制剂的[1,2,4]三唑并[1,5-a]吡啶类化合物及其应用

Also Published As

Publication number Publication date
KR20220127900A (ko) 2022-09-20
EP4105214A1 (en) 2022-12-21
EP4105214A4 (en) 2023-11-08
JP2023513599A (ja) 2023-03-31
US20230113620A1 (en) 2023-04-13
AU2020428591A1 (en) 2022-08-25
CN115066425B (zh) 2023-06-23
JP7395762B2 (ja) 2023-12-11
CA3169832A1 (en) 2021-08-19
WO2021159372A1 (zh) 2021-08-19

Similar Documents

Publication Publication Date Title
CN112739696B (zh) 作为JAK抑制剂的[1,2,4]三唑并[1,5-a]吡啶类化合物及其应用
US10961228B2 (en) JAK1 selective inhibitors
BG62002B1 (bg) (-)-[[4-(1,4,5,6-тетрахидро-4-метил-6-оксо-3-пиридазинил)фенил]хидразоно]пропандинитрил
CN102256944A (zh) 鞘氨醇-1-磷酸受体拮抗剂
CN114728967A (zh) 作为jak抑制剂的三并杂环类化合物及其应用
CN115066425A (zh) Jak抑制剂在制备治疗jak激酶相关疾病药物中的应用
WO2018005801A2 (en) Novel non-systemic tgr5 agonists
CN114096245B (zh) 作为ccr2/ccr5拮抗剂的杂环烷基类化合物
EP4149927A1 (en) Enpp1 modulators and uses thereof
CN103508931A (zh) 六氢并环戊二烯衍生物、其制备方法及其在医药上的应用
JPH0674264B2 (ja) １―（ピリジニルアミノ）―２―ピロリジノンおよびその製造法
WO2023279105A1 (en) Azetidinyl pyrimidines and uses thereof
CN115403594A (zh) 含氮三并环类化合物及其应用
CN113474318A (zh) 用作血浆激肽释放酶抑制剂的双环烷类化合物
JPH0211592A (ja) 光学活性なジヒドロピリジンホスホン酸エステル
TWI830024B (zh) 作為jak抑制劑的三並雜環類化合物及其應用
JPS6368591A (ja) 光学活性なジヒドロピリジン−５−ホスホン酸エステル
WO2017215586A1 (zh) 酰胺类衍生物、其制备方法及其在医药上的用途
JPH0331284A (ja) 新規チエノピラン誘導体、その製造方法並びにその用途
CN102796075A (zh) 苯并环庚烯类衍生物、其制备方法及医药用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant